115 related articles for article (PubMed ID: 21416481)
1. In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas.
Rinaldi A; Ponzoni M; Uccella S; Rossi D; Gaidano G; Facchetti F; Pruneri G; Tibiletti MG; Capella C; Zucca E; Doglioni C; Catapano C; Bertoni F
Hematol Oncol; 2011 Sep; 29(3):164-6. PubMed ID: 21416481
[No Abstract] [Full Text] [Related]
2. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
Cheng S; Coffey G; Zhang XH; Shaknovich R; Song Z; Lu P; Pandey A; Melnick AM; Sinha U; Wang YL
Blood; 2011 Dec; 118(24):6342-52. PubMed ID: 22025527
[TBL] [Abstract][Full Text] [Related]
3. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.
Chen L; Monti S; Juszczynski P; Daley J; Chen W; Witzig TE; Habermann TM; Kutok JL; Shipp MA
Blood; 2008 Feb; 111(4):2230-7. PubMed ID: 18006696
[TBL] [Abstract][Full Text] [Related]
4. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.
Chen L; Monti S; Juszczynski P; Ouyang J; Chapuy B; Neuberg D; Doench JG; Bogusz AM; Habermann TM; Dogan A; Witzig TE; Kutok JL; Rodig SJ; Golub T; Shipp MA
Cancer Cell; 2013 Jun; 23(6):826-38. PubMed ID: 23764004
[TBL] [Abstract][Full Text] [Related]
5. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
Uckun FM; Qazi S
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib.
Yang C; Lu P; Lee FY; Chadburn A; Barrientos JC; Leonard JP; Ye F; Zhang D; Knowles DM; Wang YL
Leukemia; 2008 Sep; 22(9):1755-66. PubMed ID: 18596745
[TBL] [Abstract][Full Text] [Related]
7. Syk inhibitors with high potency in presence of blood.
Thoma G; Blanz J; Bühlmayer P; Drückes P; Kittelmann M; Smith AB; van Eis M; Vangrevelinghe E; Zerwes HG; Che JJ; He X; Jin Y; Lee CC; Michellys PY; Uno T; Liu H
Bioorg Med Chem Lett; 2014 May; 24(10):2278-82. PubMed ID: 24726806
[TBL] [Abstract][Full Text] [Related]
8. Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice.
Uckun FM; Myers DE; Cheng J; Qazi S
EBioMedicine; 2015 Jun; 2(6):554-62. PubMed ID: 26285772
[TBL] [Abstract][Full Text] [Related]
9. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
Kaur M; Singh M; Silakari O
Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
[TBL] [Abstract][Full Text] [Related]
11. [Syk inhibitors].
Kimura Y; Chihara K; Takeuchi K; Sada K
Nihon Rinsho; 2013 Jul; 71(7):1248-52. PubMed ID: 23961675
[TBL] [Abstract][Full Text] [Related]
12. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma.
Gururajan M; Jennings CD; Bondada S
J Immunol; 2006 May; 176(10):5715-9. PubMed ID: 16670274
[TBL] [Abstract][Full Text] [Related]
13. Highly potent aminopyridines as Syk kinase inhibitors.
Castillo M; Forns P; Erra M; Mir M; López M; Maldonado M; Orellana A; Carreño C; Ramis I; Miralpeix M; Vidal B
Bioorg Med Chem Lett; 2012 Sep; 22(17):5419-23. PubMed ID: 22877633
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of WO2011134971, chiral 1,6-napthyridine Syk kinase inhibitors.
Norman P
Expert Opin Ther Pat; 2012 Mar; 22(3):335-9. PubMed ID: 22356552
[TBL] [Abstract][Full Text] [Related]
15. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
Norman P
Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
[TBL] [Abstract][Full Text] [Related]
16. New spleen tyrosine kinase inhibitors: patent applications published during 2011-2013.
Thorarensen A; Kaila N
Pharm Pat Anal; 2014 Sep; 3(5):523-41. PubMed ID: 25374321
[TBL] [Abstract][Full Text] [Related]
17. Healing the Syk through kinase inhibitors.
Rivera J; Colbert RA
N Engl J Med; 2010 Sep; 363(14):1362-4. PubMed ID: 20879886
[No Abstract] [Full Text] [Related]
18. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Riccaboni M; Bianchi I; Petrillo P
Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
[TBL] [Abstract][Full Text] [Related]
19. Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Adrián FJ; Ding Q; Sim T; Velentza A; Sloan C; Liu Y; Zhang G; Hur W; Ding S; Manley P; Mestan J; Fabbro D; Gray NS
Nat Chem Biol; 2006 Feb; 2(2):95-102. PubMed ID: 16415863
[TBL] [Abstract][Full Text] [Related]
20. The Syk kinase as a therapeutic target in leukemia and lymphoma.
Efremov DG; Laurenti L
Expert Opin Investig Drugs; 2011 May; 20(5):623-36. PubMed ID: 21438742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
